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ABSTRACT
Background: To evaluate the therapeutic benefits of the treat-to-target (T2T) strategy for 
Asian patients with early rheumatoid arthritis (RA) in Korea.
Methods: In a 1-year, multicenter, open-label strategy trial, 346 patients with early RA were 
recruited from 20 institutions across Korea and stratified into 2 groups, depending on 
whether they were recruited by rheumatologists who have adopted the T2T strategy (T2T 
group) or by rheumatologists who provided usual care (non-T2T group). Data regarding 
demographics, rheumatoid factor titer, anti-cyclic citrullinated peptide antibody titer, 
disease activity score of 28 joints (DAS28), and Korean Health Assessment Questionnaire 
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(KHAQ) score were obtained at baseline and after 1 year of treatment. In the T2T group, 
the prescription for disease-modifying antirheumatic drugs was tailored to the predefined 
treatment target in each patient, namely remission (DAS28 < 2.6) or low disease activity 
(LDA) (2.6 ≤ DAS28 < 3.2).
Results: Data were available for 163 T2T patients and 162 non-T2T patients. At the end of the 
study period, clinical outcomes were better in the T2T group than in the non-T2T group (LDA 
or remission, 59.5% vs. 35.8%; P < 0.001; remission, 43.6% vs. 19.8%; P < 0.001). Compared 
with non-T2T, T2T was also associated with higher rate of good European League Against 
Rheumatism response (63.0% vs. 39.8%; P < 0.001), improved KHAQ scores (−0.38 vs. −0.13; 
P = 0.008), and higher frequency of follow-up visits (5.0 vs. 2.0 visits/year; P < 0.001).
Conclusion: In Asian patients with early RA, T2T improves disease activity and physical 
function. Setting a pre-defined treatment target in terms of DAS28 is recommended.
Keywords: Rheumatoid Arthritis; Treatment Outcome; Treat-to-target
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease most commonly 
associated with joint pain, stiffness, and swelling.1 The ideal RA treatment goal is defined 
as remission, although low disease activity (LDA) is also considered a valuable treatment 
target.1 Treating patients with RA to a pre-specified target (treat-to-target [T2T]) represents an 
international initiative to develop recommendations for achieving optimal therapeutic outcomes 
in patients with RA.2,3 Initially, an international task force was established, which consisted of 68 
rheumatologists from 25 countries. These rheumatologists put forth a series of recommendations 
based on evidence obtained from a systematic literature review4 and expert opinion.2 Thereafter, 
the second phase of the T2T initiative was established, with the goal of promoting acceptance and 
implementation of these recommendations in daily rheumatology practice.
An international survey was conducted among rheumatologists to evaluate the extent to 
which individual components of the T2T recommendations have been incorporated into 
clinical practice.5 The Korean College of Rheumatology participated in the global survey 
and performed a separate survey in Korea alone.6 The Korean survey, administered to 
rheumatologists by the Korean National T2T Steering Committee, indicated high agreement 
with and application of the T2T recommendations in daily practice. Despite the positive 
results regarding the agreement level, the Korean T2T survey concluded that barriers 
remained for Korean rheumatologists in the application of T2T in practice due to heavy 
clinical burden and lack of support. In Korea, the 2016 cost of a rheumatology clinic visit in 
a tertiary medical center as a new patient is USD15 and a follow-up visit is USD12. Because of 
the low cost of office visits, physicians work hard to see many patients in one session. There 
is also little staff support from health educators or clinical nurse specialists. Unfortunately, 
this type of healthcare system may lead rheumatologists to practice suboptimal care, though 
treatment of patients with RA requires thorough evaluation for multi-organ involvement and 
disease progression in routine clinic visits. High demands on rheumatologists should be 
supported by the healthcare system to encourage rheumatologists to take the necessary time 
to navigate through the complicated decision-making process of treating patients with RA.
The present study aimed to observe treatment results and practice patterns related to the 
adoption of the T2T principles in the management of Korean patients with early RA. In addition, 
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we investigated whether adopting T2T recommendations is feasible in Korean practice and could 
benefit Korean patients with RA in terms of clinical and functional outcomes.
METHODS
Patients
This prospective, non-interventional study was performed in 20 institutions across Korea. 
Participating patients were followed for 12 months. To be eligible for study inclusion, 
patients had to be ≥ 20 years old; have a diagnosis established according to the American 
Rheumatism Association 1987 revised classification criteria for RA7; have early RA (2 years 
or less after diagnosis); and have moderate or high RA disease activity, with a disease activity 
score of 28 joints (DAS28) > 3.2. The study was conducted from June 2013 to December 2015.
T2T group vs. non-T2T group
Within each of the 20 participating institutions, rheumatologists applied a patient 
management strategy per their preference (i.e., T2T or non-T2T). Rheumatologists who 
adopted the T2T strategy in their practice followed the T2T principles and recommendations 
set forth by the T2T Korean National Steering Committee,6 and their patients were enrolled 
in the T2T group. Rheumatologists who did not adopt T2T followed their routine clinical 
practice, and their patients were enrolled in the non-T2T group. The non-T2T group was 
provided with usual care which includes the following: patients have follow-up appointments 
in physicians' usual schedule. There is no regular evaluation for disease activity index such 
as DAS28. The change of disease-modifying antirheumatic drugs (DMARDs) is based on 
physicians' clinical judgement. This cluster observation study design was chosen because 
it would have been difficult for the same doctor to treat patients according to different sets 
of guidelines based on treatment target assignment, and such an approach would likely 
have influenced their daily practice pattern.8 All rheumatologists participating in the study 
have been board certified for more than 10 years and are actively involved in patient care in 
university hospitals. Both T2T and non-T2T adjustments to the prescription of DMARDs were 
allowed per physician clinical decision, in agreement with the adopted treatment strategy. 
Although there was no restriction on the choice of medication, following the guidelines of 
the Korean National Health Insurance System was recommended.
Outcome measures
The following characteristics were evaluated and compared between the T2T and non-T2T 
groups: the DAS289 and Korean Health Assessment Questionnaire (KHAQ) score10 were 
determined at baseline and 12 months. DAS28 was calculated based on the erythrocyte 
sedimentation rate (ESR), with clinical remission defined as DAS28 < 2.6 and LDA defined as 
2.6 ≤ DAS28 < 3.2. Based on the extent of change in disease activity level from baseline until 
the end of the treatment (△DAS28), as well as on the actual disease activity level at the end of 
the treatment (DAS28), the European League Against Rheumatism (EULAR) response criteria 
were applied for the classification of patients as good responders (△DAS28 > 1.2; follow-up 
DAS28 ≤ 3.2), moderate responders (0.6 < △DAS28 ≤ 1.2; follow-up DAS28 > 3.2), or non-
responders. Data regarding patient adherence to follow-up visits to their rheumatologist, 
DAS28 scores, and changes in treatment regimen were also collected. The primary endpoint 
was the percentage of patients who achieved the predefined treatment target. Secondary 
endpoints included the percentage of patients who achieved remission and/or LDA, the 
change in DAS28 at 12 months from baseline (△DAS28), the percentage of patients who 
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achieved good or moderate EULAR response at 12 months, the mean change in KHAQ score 
at 12 months from baseline, the percentage of patients who achieved a KHAQ score ≤ 0.5 at 
12 months, the frequency of follow-up visits, and the changes in DMARD prescription.
Power calculation
In a large cohort study in Korea,11 the incidence of RA was 20/100,000 per year, resulting 
in 7,354 new cases of RA per year. Another epidemiologic study found that 62.9% of 
Korean patients with RA have moderate or high disease activity [unpublished data]. The 
Korean adult population (aged ≥ 20 years) was 36,765,374 in 2010, as reported by the Korea 
National Statistical Office.12 Considering that 43.1% of Korean patients with RA are treated 
by rheumatologists in hospitals,13 and estimating a 10% drop-out rate, we calculated a 
minimum sample size of 334 patients. The present study enrolled a total of 346 patients, 
which was sufficient to detect the effect of interest.
Statistical analysis
Demographic and disease-related data, as well as the results of all clinical assessments 
of patients, were summarized using descriptive statistics. For normally distributed data, 
continuous variables are presented as means with standard deviations, while non-normally 
distributed data are presented as medians with interquartile ranges (25%–75%). Frequency 
and percentage are presented for categorical variables. Mean values and frequencies of the 
parameters were compared by independent t-tests or χ2 tests, as appropriate. For non-
normally distributed variables, the Mann-Whitney U test was performed. All statistical 
evaluations were the results of 2-sided tests, with the statistical significance threshold set 
at 0.05. The 95% confidence interval was calculated using a normal approximation. All 
statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA). All 
missing data points for DAS28 and KHAQ scores were considered “missing.”
Ethics statement
The present study protocol was reviewed and approved by the Institutional Review Board of 
Seoul National University Hospital (H-1305-615-491). Written informed consent was obtained 
from all patients.
RESULTS
Baseline characteristics
Of the 346 patients who participated in this study, 21 were excluded from the analysis because 
of violation of the inclusion criteria. Among the 325 patients who satisfied the inclusion 
criteria, 163 and 162 patients were assigned to the T2T and non-T2T groups, respectively. By 
the end of the study period, 25 and 49 patients were lost to follow-up in the T2T and non-T2T 
groups, respectively. Patients in the T2T group were younger than patients in the non-T2T 
group (Table 1). Further, patients in the T2T group had a shorter disease duration than 
patients in the non-T2T group (Table 1).
Primary endpoint
In the T2T group, the percentage of patients who achieved the predefined treatment target 
was evaluated at 12 months. Each investigator chose the predefined treatment target as either 
remission or LDA for their cluster of patients. In some T2T centers, only remission was 
predefined as a treatment target, whereas LDA or remission was considered a valid target 
4/11https://jkms.org https://doi.org/10.3346/jkms.2018.33.e346
T2T for Early Rheumatoid Arthritis in Korea
in most T2T centers. Therefore, 118 patients (72.4%) had LDA or remission as a predefined 
target, while 45 patients (27.6%) had remission only as a predefined target. In the T2T 
group, the overall proportion of patients who achieved the predefined treatment target after 
12 months of treatment was 55.2% (90/163 patients). Because it is more difficult to achieve 
remission than LDA, the rate of remission in patient clusters was 35.5%, while the rate of 
LDA in patient clusters was 62.7% (P < 0.001) (Table 2). However, there was no difference in 
the rates of remission or LDA whether the target was either remission only or LDA/remission. 
Because there was no predefined treatment target in non-T2T group, the primary endpoint 
was not assessed. However, DAS28, KHAQ, and other parameters were assessed as secondary 
endpoints in the non-T2T group.
Change in DAS28-ESR
The proportion of patients who achieved clinical remission or LDA at 12 months was 59.5% 
(97/163 patients) and 35.8% (58/162 patients) in the T2T and non-T2T groups, respectively 
(P < 0.001) (Fig. 1A). The proportion of patients who achieved clinical remission at 12 
months of treatment was 43.5% (71/163 patients) and 19.7% (32/162 patients) in the T2T 
and non-T2T groups, respectively (P < 0.001). The mean change in DAS28 at 12 months 
was higher in the T2T group than in the non-T2T group (Table 3). Patients in the T2T and 
non-T2T groups had significant differences in tender joint count of 28 joints evaluated 
and ESR among the 4 components of DAS28 (Table 3). Further analysis was performed with 
data from patients who had DAS28 scores available at both baseline and the end of the study 
period, namely 138 patients in the T2T group and 113 patients in the non-T2T group (Fig. 1B). 
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Table 1. Baseline characteristics of patients with early RA
Characteristics T2T group (n = 163) Non-T2T group (n = 162) P value
Gender, women 129 (79.1) 135 (83.3) 0.33
Age, yr 52.0 (43.0–60.0) 55.0 (45.0–64.0) 0.01
Duration of disease, mon 3.0 (0.0–8.0) 4.0 (1.0–13.0) < 0.01
RF 120 (73.6) 116 (71.6) 0.68
Anti-CCP 123 (75.9) 114 (70.4) 0.22
TJC28 4.0 (2.0–7.0) 4.0 (2.0–7.0) 0.29
SJC28 3.0 (1.0–5.0) 3.0 (2.0–5.0) 0.06
ESR, mm/hr 38.0 (24.0–58.0) 31.0 (19.0–59.0) 0.18
PGA, mm 50.0 (30.0–64.0) 50.0 (30.0–62.0) 0.78
DAS28 4.76 (4.07–5.37) 4.69 (3.88–5.43) 0.39
KHAQ score 0.63 (0.38–1.13) 0.50 (0.13–1.25) 0.22
Values are expressed as medians (interquartile ranges 25%–75%) or number (%). Patients were stratified into a 
T2T group and a non-T2T group, according to the treatment strategy applied for 12 months. DAS28 was measured 
using ESR.
RA = rheumatoid arthritis, T2T = treat-to-target, RF = rheumatoid factor, anti-CCP = anti-cyclic citrullinated 
peptide antibodies, TJC28 = tender joint count of 28 joints evaluated, SJC28 = swollen joint count of 28 joints 
evaluated, ESR = erythrocyte sedimentation rate, PGA = patient global assessment, DAS28 = disease activity 
score of 28 joints, KHAQ = Korean Health Assessment Questionnaire.
Table 2. Proportion of patients achieving the predefined treatment target in the T2T group
Predefined treatment target
Remission only (n = 45) LDA or remission (n = 118) Total (n = 163) P valuea
Target achievement 16 (35.5) 74 (62.7) 90 (55.2) 0.001
Remission 16 (35.5) 55 (46.6) 71 (43.5) 0.203
LDA or remission 23 (51.1) 74 (62.7) 97 (59.5) 0.177
LDA 7 (15.5) 19 (16.1) 26 (15.9) 0.932
Values are expressed as number (%). Patients were stratified into a remission group and LDA group according to 
the predefined therapeutic target.
T2T = treat-to-target, LDA = low disease activity.
aDifferences were compared between patients with a predefined target of remission versus LDA or remission.
At baseline, there was no difference between the groups regarding the proportion of patients 
with moderate or high disease activity. However, at 12 months, the proportion of patients 
with moderate or high disease activity was lower in the T2T group than in the non-T2T group 
(29.7% vs. 48.7%, P = 0.002) (Fig. 1B).
Clinical efficacy by EULAR response
According to DAS28 values after 12 months of treatment, the proportion of patients that had 
a good EULAR response was 63.0% (87/138 patients) and 39.8% (45/113 patients) in the T2T 
and non-T2T groups, respectively (P < 0.001) (Fig. 1C).
6/11https://jkms.org https://doi.org/10.3346/jkms.2018.33.e346
T2T for Early Rheumatoid Arthritis in Korea
Success to
remission or LDA
% %
%
Success to
remission 
0
60
50
70
40
20
10
30
A
T2T Non-T2T T2T Non-T2T
Baseline At 12 months
0
80
60
100
40
20
B
T2T
Non-T2T
Remission
Low activity
Moderate activity
High activity
T2T Non-T2T
0
80
60
100
40
20
C
Good EULAR response
Moderate EULAR response
Non-response
P < 0.001
P < 0.001
Fig. 1. Disease activity in patients with early RA with high and moderate activity at baseline. Patients were stratified into a T2T group and a non-T2T group, 
according to the treatment strategy applied for 12 months. (A) Treatment success defined as remission or LDA, quantified in terms of DAS28. (B) Disease activity 
(DAS28) at baseline and at the end of the study period (12 months from baseline). (C) EULAR response to treatment. 
RA = rheumatoid arthritis, T2T = treat-to-target, LDA = low disease activity, DAS28 = disease activity score of 28 joints, EULAR = European League Against Rheumatism.
Table 3. Mean change in disease activity and KHAQ scores from baseline in patients with early RA
T2T group Non-T2T group P value
TJC28 −3.0 (−6.0, −1.0) −2.0 (−4.0, −1.0) 0.002
SJC28 −3.0 (−5.0, −1.0) −2.0 (−4.0, −1.0) 0.111
ESR, mm/hr −18.0 (−33.0, −5.0) −9.0 (−24.0, 1.0) 0.003
PGA, mma −21.74 ± 27.87 −17.65 ± 24.12 0.216
DAS28a −2.20 ± 1.47 −1.37 ± 1.33 < 0.001
KHAQ score −0.38 (−0.63, 0.00) −0.13 (−0.50, 0.00) 0.008
Values are expressed as medians (interquartile ranges 25%–75%) or number (%). Patients were stratified into a 
T2T group and a non-T2T group, according to the treatment strategy applied for 12 months. DAS28 was measured 
using ESR.
KHAQ = Korean Health Assessment Questionnaire, RA = rheumatoid arthritis, T2T = treat-to-target, TJC28 = 
tender joint count of 28 joints evaluated, SJC28 = swollen joint count of 28 joints evaluated, ESR = erythrocyte 
sedimentation rate, PGA = patient global assessment, DAS28 = disease activity score of 28 joints.
aValues are expressed as means (standard deviations).
Physical function
At 12 months, evaluation of the mean change in KHAQ scores indicated significantly more 
pronounced improvement in patients in the T2T group than in the non-T2T group (Table 3). 
Among several KHAQ components, eating and grip activities were improved to a significantly 
higher extent in patients in the T2T group (Supplementary Table 1).
Frequency of visits and changes in medication
During the 12 months of follow-up visits, patients in the T2T group made more frequent 
visits for follow-up than the non-T2T group (Table 4). DAS28 was more frequently evaluated 
in the T2T group than in the non-T2T group (Table 4). DMARD prescriptions were more 
frequently changed in the T2T group than in the non-T2T group (Table 4).
DISCUSSION
The treatment of RA has dramatically evolved over the past several years, with a shift toward 
more aggressive treatment approaches in the early stages of the disease, combination use 
of multiple DMARDs, and the emergence of biologic treatment. Although several clinical 
trials have demonstrated the benefits of the T2T strategy, there are limitations to adopting 
this approach in daily practice.14 In particular, each health service system is characterized by 
a certain level of patient awareness, medical costs, accessibility to rheumatology care, and 
availability of biologics, which can differ from country to country. To our knowledge, this is 
the first T2T clinical trial in Asia to demonstrate the benefits of the T2T strategy. Specifically, 
we found that, compared with the non-T2T group, patients in the T2T group achieved higher 
rates of remission or LDA and better functional outcomes.
The benefits of the T2T strategy include superior disease activity control, better functional 
outcomes, and long-term economic benefits.14,15 However, there have been very few reports 
in countries outside of Europe and the United States. A small intensive treatment trial was 
performed in Hong Kong with a historical control group.16 Nevertheless, it is important 
to evaluate the feasibility of T2T in Korea because of the differences in ethnic background, 
access to medical care, patient preference toward traditional medicine such as acupuncture, 
and physician willingness to adopt the T2T strategy. The Korean National Medical Insurance 
System allows easy referrals to any medical center that a patient prefers.17 As a result, 
most academic centers run busy rheumatology outpatient clinics to handle a wide range 
of diseases from osteoarthritis to complicated vasculitis. Reimbursement for expensive 
medication can be tightly controlled by the national medical insurance system, although 
most biologics were available during the study period (with the exception of certolizumab 
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Table 4. Difference in treatment patterns of patients with early RA in the T2T group and non-T2T group
T2T group Non-T2T group P value
Total No. of visits over 12 months 5.0 (4.0–9.0) 2.0 (2.0–3.0) < 0.001
No. of visits measuring DAS28 5.0 (4.0–7.0) 2.0 (1.0–2.0) < 0.001
Percentage of visits measuring DAS28 100.0 (80.0–100.0) 100.0 (100.0–100.0) 0.041
No. of visits changing DMARDsa 2.0 (1.0–3.0) 1.0 (1.0–1.0) < 0.001
Percentage of visits changing DMARDs 60.0 (33.3–100.0) 100.0 (33.3–100.0) 0.187
Values are expressed as medians (interquartile ranges 25%–75%). Patients were stratified into a T2T group and a 
non-T2T group, according to the treatment strategy applied for 12 months. DAS28 was measured using ESR.
RA = rheumatoid arthritis, T2T = treat-to-target, DAS28 = disease activity score in 28 joints, DMARD = disease-
modifying antirheumatic drug, ESR = erythrocyte sedimentation rate.
aThe baseline visit and the 12 months visit were excluded for assessment of changing DMARDs.
and tofacitinib). A brief analysis demonstrated that the T2T trial in Korea is comparable to 
previous trials conducted in European countries (Table 5). It is interesting to see that the 
benefits of T2T are reproducible in Korea, which has a different medical system than those in 
European countries.
There are several obstacles to implementing the T2T strategy in Korea. Considering the fact 
that physician's clinical judgement for remission has low concordant rate with the Boolean 
criteria in the Korean Observational Study Network for Arthritis (KORONA) cohort,18 it 
is necessary to set the treatment target. Given the busy daily schedule in Korean clinics, 
it is difficult to evaluate complex indicators of treatment target, such as DAS28. Without 
proper incentive to measure DAS28, it will be difficult to establish an appropriate treatment 
target during a short routine visit to the clinic. Of note, smart phone or computer software 
applications make it fast and easy to calculate a patient's DAS.19 In addition, frequent visits to 
the rheumatologist can be difficult for some patients. Furthermore, because the availability of 
rheumatologists is generally low in some areas, many patients with RA seek medical services 
from practitioners of primary care, other specialties (orthopedics or pain specialists), or even 
Korean traditional medicine, with a focus on pain management rather than disease activity 
management. Medication nonadherence is common in Korean RA patients. According 
to Korean multicenter clinical data, the medication nonadherence rate was 54.1%.20 
However, our study demonstrated that frequent visits to the rheumatologist led to beneficial 
adjustments to DMARD prescriptions and, ultimately, better disease control. Therefore, the 
T2T strategy should be considered by Korean rheumatologists and policymakers for future 
planning to improve patient outcomes.
Compared with the non-T2T group, the T2T group had better functional outcomes, measured 
in terms of KHAQ scores. This finding is important because, in RA, functional outcomes 
are strongly associated with economic impact.21 The T2T strategy could be more expensive 
than current daily practice in Korea, with more frequent visits and greater medication cost. 
However, better functional outcomes and the prevention of joint damage and disability can 
reduce long-term medical costs.22 Consistent with our finding, low DAS28-ESR is associated 
with low KHAQ score in a large Korean RA cohort (KORONA).23
A strength of our study is that patients were recruited from 20 academic medical centers, 
which cover the majority of rheumatology services across Korea.24 Therefore, our data 
represent current practice patterns in the management of patients with RA in Korea. There 
are also limitations to our study. First, there was no randomization within academic centers, 
which may have influenced the outcome. Second, details of medication and adverse effects 
were not collected due to budget restrictions. Third, since this was a non-interventional study 
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Table 5. T2T trials for early RA using DAS28 as a treatment target
Randomization Study duration, (mon) Strategy arm Study target Target achievement rate
Goekoop-Ruiterman et al.26 Yes 18 Tight control (n = 234)
vs. usual care (n = 201)
DAS28 ≤ 2.4 31% vs. 18%
Soubrier et al.27 (GUEPARD/ESPOIR) No 12 Targeted group (n = 65) 
vs. routine group (n = 130)
DAS28 ≤ 3.2 63.1% vs. 43.8%
Schipper et al.28 (DREAM) No 12 Tight control (n = 126) 
vs. usual care (n = 126)
DAS28 < 2.6 55% vs. 30%
Korean T2T study (present) No 12 T2T (n = 163) 
vs. non-T2T (n = 162)
DAS28 < 2.6 43.6% vs. 19.7%
DAS28 ≤ 3.2 59.5% vs. 35.8%
T2T = treat-to-target, RA = rheumatoid arthritis, DAS28 = disease activity score of 28 joints, GUEPARD = Guérir la Polyarthrite Rhumatoide Débutante, ESPOIR = 
Etude et Suivi des Polyarthrites Indifférenciées Récentes, DREAM = Dutch Rheumatoid Arthritis Monitoring.
of daily clinical practice, it was unfeasible to thoroughly control factors that could influence 
the data regarding clinical effectiveness. In addition, it is possible that the treatment benefits 
in the T2T group could be partly associated with patient demographics, as the patients in the 
T2T group were younger with a shorter disease duration than patients in the non-T2T group.
Increasing evidence from randomized controlled trials suggests that in patients with early 
RA, monitoring disease activity with subsequent adjustment of medication, in the aim of 
achieving predefined treatment targets, can lead to better outcomes than those achieved 
via usual care.25 Based on the findings of the present study, the implementation of T2T 
in Korean clinical practice is feasible and may lead to positive outcomes in patients with 
RA. To confirm the generalizability of these findings, further studies, including large 
randomized trials, are necessary.
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